Teva Pharmaceutical Industries (TEVA) said late Monday the US Food and Drug Administration has approved Degevma as a biosimilar to Xgeva.
Degevma is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, it said.
The drug is also indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy, Teva said.
Teva said it expects to launch Degevma and Ponlimsi in the US in the coming months. Ponlimsi was approved in March.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.